Biodelivery Sciences buy klostergang
Zusammenfassung
Diese Einschätzung wurde am 17.06.21 mit einem Endkurs von 2,94 € beendet. Die Einschätzung konnte insgesamt eine Rendite von 12,39 % verzeichnen. klostergang hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
| Name | 1W | 1M | 1J | 3J |
|---|---|---|---|---|
| Biodelivery Sciences | - | - | - | - |
| iShares Core DAX® | 0,48 % | -0,04 % | 13,34 % | 17,33 % |
| iShares Nasdaq 100 | 1,29 % | 0,50 % | 40,10 % | 50,53 % |
| iShares Nikkei 225® | 1,30 % | -2,13 % | 19,86 % | 4,94 % |
| iShares S&P 500 | 0,83 % | 0,19 % | 29,76 % | 43,43 % |
Kommentare von klostergang zu dieser Einschätzung
In der Diskussion Biodelivery Sciences
BDSI quite attractive at current levels
The overall risk/reward profile of this stock quite attractive at current levels.
Roth Capital reiterated its Buy rating and $4.50 a share price target on BDSI.
Roth's analyst notes,
"We recently met with the management of BioDelivery Sciences. Our key takeaway is that the share price driver over the coming six months is likely to be prescription data for the pain drug Belbuca. Management remains optimistic and the cash runway has recently been strengthened. Maintain Buy rating. Key takeaways from our meetings with BDSI
management include: Business plan update. It appears that the sales operation is already cash flow breakeven."
BDSI has secured two new U.S. patents covering all three of its FDA-approved products: BELBUCA (buprenorphine) buccal film, BUNAVAIL (buprenorphine and naloxone) buccal film and ONSOLIS (fentanyl buccal soluble film). One patent (U.S. Patent Application 15/212912) covers the composition of
the BioErodible MucoAdhesive drug delivery technology for BELBUCA and BUNAVAIL and the other ('288 patent) extends protection on ONSOLIS until July 2027.
Beendete Einschätzungen von klostergang zu Biodelivery Sciences
Biodelivery Sciences
10.04.17
10.10.17
10.10.17
